

Corporate Seminar

J Japanese Session / **E** English Session

9-Oct (Fri) 12 : 05 – 12 : 50

JLS1-1 Molecular pathogenesis and therapeutic strategy of DLBCL

【No.1 Kyoto International Conference Center 1F Main Hall】

Chair Shinya Rai (Department of Hematology and Rheumatology, Kindai University Faculty of Medicine)

Speaker Daisuke Ennishi (Department of Medical Oncology, Okayama University)

Sponsor CHUGAI PHARMACEUTICAL CO., LTD.

ELS1-2 US Lessons: Optimizing Outcomes in CAR T Therapy for DLBCL

【No.2 Kyoto International Conference Center 2F Room A】

Chair Seitaro Terakura (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine)

Speaker Miguel-Angel Perales (Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College)

Sponsor Gilead Sciences K.K.

ELS1-3 An approach to lower risk MDS

【No.3 Kyoto International Conference Center 2F Room B-1】

Chair Yasushi Miyazaki (Japanese Red Cross Nagasaki Genbaku Hospital)

Speaker Guillermo Garcia-Manero (Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center)

Sponsor Bristol Myers Squibb K.K.

JLS1-4 Management of Infectious Complications Associated with Cellular Immunotherapy

【No.4 Kyoto International Conference Center 2F Room B-2】

Chair Miki Ando (Department of Hematology, Juntendo University Faculty of Medicine)

Speaker Hideki Goto (Department of Hematology / Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital)

Sponsor Takeda Pharmaceutical Company Limited

■LS1-5 Rethinking the Management of Fungal Infections in AML

[No.5 Kyoto International Conference Center 1F Sakura]

Chair Yoshinobu Kanda (Division of Hematology, Department of Medicine, Jichi Medical University. All Rights Reserved. / Division of Hematology, Jichi Medical University Saitama Medical Center)

Risk of invasive fungal disease in the era of novel AML therapies and treatment strategies guided by suspected fungal pathogens

Speaker Shun-ichi Kimura (Division of Hematology, Jichi Medical University Saitama Medical Center)

Treatment Strategies for Invasive Fungal Disease after Allogeneic Hematopoietic Cell Transplantation: A Focus on Drug-Drug Interactions

Speaker Junya Kanda (Department of Hematology, Graduate School of Medicine, Kyoto University)

Sponsor ASAHI KASEI THERAPEUTICS CORPORATION

■LS1-6 Mastering Infection Control in the Era of CAR-T Cell Therapy and Bispecific Antibodies – The Frontline of Hypogammaglobulinemia Management –

[No.6 Kyoto International Conference Center 1F Room C-1]

Chair Chiaki Nakaseko (Department of Hematology, International University of Health and Welfare School of Medicine)

Speaker Kentaro Serizawa (Department of Hematology and Rheumatology, Kindai University Faculty of Medicine)

Sponsor CSL Behring K.K.

■LS1-7 Current positioning of Belumosudil for the treatment of chronic GVHD

[No.7 Kyoto International Conference Center 1F Room C-2]

Chair Shinichi Kako (Division of Hematology, Jichi Medical University Saitama Medical Center)

Speaker Souichi Shiratori (Department of Hematology, Hokkaido University)

Sponsor Meiji Seika Pharma Co., Ltd.

■LS1-8 Immune Thrombocytopenia: From Autoantibody-Mediated Pathogenesis to the Clinical Impact of FcRn Inhibitor

[No.8 Kyoto International Conference Center 1F Room D]

Chair Yoshitaka Miyakawa (Department of Hematology, Saitama Medical University Hospital)

Pathogenesis of Autoantibody-Mediated Immune Thrombocytopenia and Its Impact on Platelet Function

Speaker Sachiko Kanaji (Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University)

Risk-Adapted Treatment Strategies in ITP: Insights into Patient Profiles from Clinical Experience with FcRn Inhibitor

Speaker Shikiko Ueno (Department of Transfusion Medicine and Cell Therapy, Kumamoto University Hospital)

Sponsor argenx Japan K.K.

LS1-9

[No.9 Kyoto International Conference Center 1F Room E]

Chair Koichi Akashi (Department of Medicine and Biosystemic Science,
Kyushu University Graduate School of Medicine (仮))

Advances in COVID-19 Management for Patients with Hematologic Diseases: From Prevention of Severe Illness to Long-Term Care

Speaker Hiroyuki Kunishima (Department of Infectious Diseases, St. Marianna
University School of Medicine (仮))

Update on the Treatment of Antimicrobial-Resistant Gram-Negative Bacterial Infections in Patients with Hematologic Malignancies

Speaker Souhei Harada (Department of Microbiology and Infectious Diseases,
Toho University School of Medicine (仮))

Sponsor Shionogi & Co., Ltd.

LS1-10

[No.10 Kyoto International Conference Center 1F Room F]

Chair Masao Ogata (Department of Medical Oncology and Hematology, Oita
University Faculty of Medicine)

Expansion of cGVHD treatments in the ECP era

Speaker Yasuyuki Arai (Department of Cytotherapy, Kyoto University
Hospital)

Clinical practice in cGVHD aiming to be steroid-free

Speaker Mitumasa Watanabe (Department of Hematology, Hyogo Prefectural
Amagasaki General Medical Center)

Sponsor Therakos Japan

LS1-12 Treatment strategy for PTCL 2026

[No.12 Kyoto International Conference Center 1F Room H]

Chair Ayumi Fujimoto (Division of Hematology/Oncology, Department of
Internal Medicine, Kameda Medical Center)

Speaker Nobuhiko Yamauchi (Cancer Institute Hospital of JFCR, Department
of Hematology Oncology)

Sponsor DAIICHI SANKYO COMPANY, LIMITED.

■LS1-13 QOL-Boosting SDM in Haemophilia Care: What Referring Paediatricians and Receiving Haematologists Can Do

[No.13 Kyoto International Conference Center 2F Room I]

Chair Atsushi Manabe (Teine Keijinkai Hospital, Department of Pediatrics)
"Take it as prescribed" Is Not Enough: SDM to Build Adherence and Smooth Transition

Speaker Moeko Hino (Department of Pediatrics, Division of Community Care and Patient Care Service, Transitional Care Center, Chiba University Hospital)

SDM as "Priority Alignment": Diverse Needs and the Physician-Patient Perception Gap

Speaker Ei Kinai (Department of Laboratory Medicine, Tokyo Medical University)

Sponsor Medical Affairs Department, Novo Nordisk Pharma Ltd.

■LS1-15 Targeting IFN- γ in Hyperinflammatory Diseases: Emerging Therapeutic Strategies for HLH/MAS

[No.15 Kyoto International Conference Center 2F Room K]

Chair Hideaki Nakajima (Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine)

Speaker Tomoyuki Asano (Department of Rheumatology, Fukushima Medical University School of Medicine)

Sponsor Sobi Japan

■LS1-16 Current Perspectives on the Treatment of Primary CNS Lymphoma: The Role of Thiotepa-Based Autologous Stem Cell Transplantation

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

Chair Motoko Yamaguchi (Department of Hematological Malignancies, Mie Graduate School of Medicine)

Speaker Fumiya Wada (Department of Hematology, Graduate School of Medicine, Kyoto University)

Sponsor Sumitomo Pharma Co., Ltd.

■LS1-17 Practical Perioperative Management in Paroxysmal Nocturnal Hemoglobinuria –Based on the Reference Guide –

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

Chair Hiroki Yamaguchi (Department of Hematology, Nippon Medical School)

Speaker Akihiko Goto (Center for Hematologic Intractable Diseases, Nerima Hikarigaoka Hospital/Department of Hematology, Tokyo Medical University)

Sponsor Alexion Pharma GK

■LS1-18 Treatment of Relapsed/Refractory Multiple Myeloma in the context of the Immune microenvironment

【No.18 The Prince Kyoto Takaragaike B2F Gold Room】

Chair Kenshi Suzuki (Department of Hematology Myeloma and Amyloidosis Center, Japanese Red Cross Medical Center)

Immunotherapy and Immune Microenvironment of Multiple Myeloma

Speaker Toshiki Ochi (Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine)

Revisiting RRMM Treatment Through the Immune Microenvironment

Speaker Hideto Tamura (Department of Hematology, Dokkyo Medical University Saitama Medical Center)

Sponsor Medical Affairs Division, Johnson & Johnson

10-Oct (Sat) 11 : 30—12 : 15

■LS2-1 TBD

【No.1 Kyoto International Conference Center 1F Main Hall】

Chair Satoshi Yamazaki (Division of Cell Regulation, The Institute of Medical Science, The University of Tokyo)

Speaker Yoshikane Kikushige (Department of Medicine and Biosystemic Science, Kyushu University, Faculty of Medicine, Japan)

Sponsor AbbVie GK

■LS2-2 Transforming the management of early relapse multiple myeloma with T-cell redirecting therapy

【No.2 Kyoto International Conference Center 2F Room A】

Chair Naoki Hosen (Dept. of Hematology and Oncology, The University of Osaka Graduate School of Medicine)

Speaker Luciano J Costa (UAB, The University of Alabama at Birmingham)

Sponsor Johnson & Johnson

■LS2-3 Reducing the Burden: A Patient-Focused Approach to “IsaVRd → IsaRd Therapy” and Advances in Modes of Administration

【No.3 Kyoto International Conference Center 2F Room B-1】

Chair Junya Kuroda (Division of Hematology, Department of Internal Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science)

Speaker Keichiro Mihara (International Center for Cell and Gene Therapy, Fujita Health University Graduate School of Medicine, Department of Cellular Immunotherapies for Cancer, Fujita Health University)

Speaker Salomon Manier (Department of Hematology, Université de Lille, CHU Lille, Lille, France)

Sponsor Sanofi K.K.

LS2-4 The Evolving Treatment Landscape of Myelofibrosis and the Role of Fedratinib

[No.4 Kyoto International Conference Center 2F Room B-2]

- Chair** Toshihiro Miyamoto (Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University)
- Speaker** Kazuya Shimoda (Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki)
- Sponsor** Recordati Rare Diseases Japan K.K.

LS2-5 Treatment Strategies for Newly Diagnosed CML-CP

[No.5 Kyoto International Conference Center 1F Sakura]

- Chair** Akifumi Takaori (Department of Hematology, Graduate School of Medicine, Kyoto University)
- Asciminib in Frontline CML: ASC4FIRST and ASC4START**
- Speaker** Tim H. Brümmendorf (Department of Hematology and Oncology, Center for Integrated Oncology Aachen, University Hospital RWTH Aachen, Germany)
- The Current Status of CML Management with Asciminib and the Path to TFR**
- Speaker** Naoto Takahashi (Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine)
- Sponsor** Novartis Pharma K.K.

LS2-6 First-line Treatment Strategies for Japanese Patients with CLL: Time-Limited Therapy and Continuous Therapy with Acalabrutinib

[No.6 Kyoto International Conference Center 1F Room C-1]

- Chair** Jun Takizawa (Department of Hematology, Niigata University Medical and Dental Hospital)
- Speaker** Hirohiko Shibayama (Department of Hematology, Osaka National Hospital, National Hospital Organization)
- Sponsor** AstraZeneca K.K.

LS2-7 The Role of Elrexfio in Relapsed/Refractory Multiple Myeloma

[No.7 Kyoto International Conference Center 1F Room C-2]

- Chair** Hirono Iriuchishima (National Hospital Organization Shibukawa Medical Center)
- Speaker** Taku Kikuchi (Department of Hematology, Japanese Red Cross Medical Center)
- Sponsor** Pfizer Japan Inc.

LS2-8 Optimizing the management of R/R ALL: how to sequence immunotherapies

[No.8 Kyoto International Conference Center 1F Room D]

Chair Motohiro Kato (Department of Pediatrics, the University of Tokyo)
Speaker Elias Jabbour (Leukemia, UT MD Anderson Cancer Center)
Sponsor Amgen K.K./Astellas Pharma Inc.

LS2-9 CPX-351 in High-Risk AML: Clinical Significance and a New Therapeutic Strategy Based on Liposomal Formulation

[No.9 Kyoto International Conference Center 1F Room E]

Chair Hisayuki Yokoyama (Division of Hematology and Cell Therapy, Yamagata University School of Medicine)
Speaker Noboru Asada (Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)
Sponsor Nippon Shinyaku Co., Ltd.

LS2-10 CREB3L1: A Promising Novel Diagnostic Marker for Myeloproliferative Neoplasms

[No.10 Kyoto International Conference Center 1F Room F]

Chair Norio Komatsu (Development of Hematology, Advanced Hematology, Graduate School of Medicine, Juntendo University)
Speaker Yoko Eda Hiro (Development of Hematology, Advanced Hematology, Graduate School of Medicine, Juntendo University)
Sponsor SRL, Inc./H.U. Frontier, Inc.

LS2-12 Prognostic Assessment of ATL and Multidisciplinary Treatment Collaboration

[No.12 Kyoto International Conference Center 1F Room H]

Chair Kisato Nosaka (Cancer Center, Kumamoto University Hospital)
ATL Management from a Dermatologist's Perspective: Assessment of Cutaneous Involvement and Treatment Strategies
Speaker Kazuyasu Fujii (Department of Dermatology, Kindai University Hospital)
Recent Topics in Clinical Laboratory Testing for HTLV-1/ATL
Speaker Shigeo Fuji (Department of Hematology, Osaka International Cancer Institute)
Sponsor Minophagen Pharmaceutical Co., Ltd.

LS2-13 Treatment Strategies for Relapsed/Refractory PTCL with Consideration of Tumor Immunity

[No.13 Kyoto International Conference Center 2F Room I]

Chair Rika Sakai (Kanagawa Cancer Center)
Speaker Tatsuro Jo (Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital)
Sponsor Eisai Japan

■LS2-14 Management of Fungal Infections in Hematology and the Role of AmBisome

[No.14 Kyoto International Conference Center 2F Room J]

- Chair** Takahiro Fukuda (Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
- Speaker** Shinsuke Takagi (Department of Hematology, Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital)
- Sponsor** Sumitomo Pharma Co., Ltd.

■LS2-15 Total Management of Acquired Hemophilia A – A Practical Approach from Hemostatic Control to Rebleeding Prevention –

[No.15 Kyoto International Conference Center 2F Room K]

- Chair** Yoshiyuki Ogawa (Division of Blood transfusion, Gunma University Hospital)
- Speaker** Masato Bingo (Department of Laboratory Medicine, Tokyo Medical University Hospital)
- Sponsor** KM Biologics Co.,Ltd./Japan Blood Products Organization

■LS2-16 Well-Being in Multiple Myeloma Treatment –The Role of Oral Proteasome Inhibitors in Elderly Patients–

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

- Chair** Yoichi Imai (Department of Hematology and Oncology, Dokkyo Medical University)
- Speaker** Takashi Ikeda (Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center)
- Sponsor** Takeda Pharmaceutical Company Limited

■LS2-17 Optimizing treatment strategies for patients with CLL in the era of personalized medicine

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

- Chair** Kensuke Kojima (Department of Hematology, Kochi Medical School, Kochi University)
- Speaker** Tomohiko Kamimura (Department of Hematology, Harasanshin Hospital)
- Sponsor** BeOne Medicines Japan

■LS2-18 State of the art in diagnosis and management in Waldenström macroglobulinemia

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

- Chair** Koji Izutsu (Department of Hematology, National Cancer Center Hospital)
- Speaker** Naohiro Sekiguchi (Department of Hematology, National Hospital Organization Disaster Medical Center)
- Sponsor** ONO PHARMACEUTICAL CO., LTD.

11-Oct (Sun) 11 : 50—12 : 35

LS3-1 Optimizing Treatment Strategy for Essential Thrombocythemia Live Recording On-demand

[No.1 Kyoto International Conference Center 1F Main Hall]

- Chair** Kohshi Ohishi (Transfusion Medicine and Cell Therapy, Mie university Hospital)
- Speaker** Harinder Gill (Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong)
- Sponsor** PharmaEssentia Japan KK

LS3-2 Expanding Options, Improving Outcomes: Managing Relapsed DLBCL

[No.2 Kyoto International Conference Center 2F Room A]

- Chair** Mamiko Sakata-Yanagimoto (Department of Hematology Institute of Medicine University of Tsukuba)
- Speaker** Nancy L. Bartlett (Washington University School of Medicine, Siteman Cancer Center, St Louis, MO)
- Sponsor** CHUGAI PHARMACEUTICAL CO., LTD.

LS3-3 Considering the Early Use of BLENREP in Relapsed/Refractory Multiple Myeloma

[No.3 Kyoto International Conference Center 2F Room B-1]

- Chair** Shinsuke Iida (Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences)
- Speaker** Tomoaki Fujisaki (Department of Hematology, Japanese Red Cross Matsuyama Hospital)
- Sponsor** GlaxoSmithKline K.K.

LS3-4 Current Landscape and Future Directions of Therapy for FLT3-Mutated AML

[No.4 Kyoto International Conference Center 2F Room B-2]

- Chair** Takanori Teshima (Department of Hematology, Hokkaido University Faculty of Medicine)
- Speaker** Hitoshi Kiyoi (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine)
- Sponsor** Astellas Pharma Inc.

LS3-5 Shifting Paradigms in R/R Follicular Lymphoma

[No.5 Kyoto International Conference Center 1F Sakura]

- Chair** Mineo Kurokawa (Department of Hematology and Oncology, The University of Tokyo Hospital)
- Speaker** Junichiro Yuda (Department of Hematology & Experimental Therapeutics, National Cancer Center Hospital East)
- Sponsor** Genmab K.K./AbbVie GK

■LS3-6 The positioning in fostamatinib in chronic ITP: An integrated interpretation of the Spanish GEPTI recommendations and real-world clinical data from Spain

[No.6 Kyoto International Conference Center 1F Room C-1]

- Chair** Haruko Tashiro (Department of Hematology, Teikyo University)
Speaker María Eva Mingot Castellano (Hematology Department, Blood Bank and Tissue Procurement Unit, Virgen del Rocío University Hospital, Seville)
Sponsor KISSEI PHARMACEUTICAL CO.,LTD.

■LS3-7 Treatment Strategy for Relapse and Refractory Follicular Lymphoma

[No.7 Kyoto International Conference Center 1F Room C-2]

- Chair** Katsuya Fujimoto (Department of Hematology, NHO Hokkaido Cancer Center)
Speaker Laurie H Sehn (Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia)
Sponsor Incyte Biosciences Japan G.K.

■LS3-8 Advances in Ph+ Leukemia: Evolving Strategies in Diagnosis and Treatment

[No.8 Kyoto International Conference Center 1F Room D]

- Chair** Tetsuya Nishida (Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan)
Speaker Koji Sasaki (Department of Clinical Laboratory Medicine, Institute of Science Tokyo,Japan)
Sponsor Otsuka Pharmaceutical Co., Ltd.

■LS3-9 Navigating Treatment Choices in Bone Marrow Failure–Associated PNH: Insights from the New Guidelines and the Evolving Role of Proximal Complement Inhibitors

[No.9 Kyoto International Conference Center 1F Room E]

- Chair** Junichi Nishimura (Department of Hematology and Oncology Graduate School of Medicine, Osaka University)
Speaker Kohei Hosokawa (Department of Hematology, Kanazawa University Hospital)
Sponsor Sobi Japan/Asahi Kasei Therapeutics Corporation

■LS3-10 IMiDs in Multiple Myeloma: Current Status and Future Perspectives

[No.10 Kyoto International Conference Center 1F Room F]

- Chair** Ito Tomoki (Kansai Medical Univresity Hematology and Oncology)
Speaker Yoshiaki Kuroda (Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Department of Transfusion Medicine)
Sponsor Fuji Pharma Co.,Ltd.

LS3-12 Reconsidering Prophylaxis in Congenital Bleeding and Thrombotic Disorders: Congenital Hemophilia A and Congenital TTP

[No.12 Kyoto International Conference Center 1F Room H]

Chair Katsuyoshi Koh (Department of Hematology/Oncology, Saitama Children's Medical Center)

Speaker Satoshi Higasa (Department of Hematology, School of Medicine, Hyogo Medical University)

Sponsor Japan Medical Office, Takeda Pharmaceutical Company Limited

**LS3-13 Beyond Morphological Remission
—Molecular MRD Assessment and Clinical Applications in AML—**

[No.13 Kyoto International Conference Center 2F Room I]

Chair Yosuke Minami (National Cancer Center Hospital East, Hematology)

Speaker Koichi Onodera (Tohoku University Hospital, Hematology)

Sponsor INVIVOSCRIBE / LabPMM

LS3-15 Onco-Nephrology in the Management of Hematologic Malignancies: Focus on delayed Methotrexate elimination.

[No.15 Kyoto International Conference Center 2F Room K]

Chair Noriko Fukuhara (Tohoku University Graduate School of Medicine, Department of Hematology)

Speaker Wataru Munakata (National Cancer Center Hospital, Department of Hematology)

Sponsor OHARA Pharmaceutical Co., Ltd.

LS3-16 Up-to-Date Targeted Therapy for Patients with Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

Chair Yoshinobu Maeda (Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)

Optimizing Treatment for IDH1-Mutated Acute Myeloid Leukemia: Integration of Tibsovo and Practical Management in Real-World Clinical Practice

Speaker Goichi Yoshimoto (The Department of Hematology, Saga-Ken Medical Centre Koseikan)

Sponsor Nihon Servier Co., Ltd.

LS3-17

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

Chair Yuju Ohno (Department of Hematology, Kitakyushu Municipal Medical Center)

FN Prophylaxis Strategies in Lymphoma: Insights from Real-World Data

Speaker Kensuke Matsuda (Department of Hematology and Oncology, National Cancer Center Hospital East)

The Impact of G-CSF on Supportive Care in Hematologic Malignancies: Historical Perspectives, Evidence, and Future Directions in FN Prophylaxis

Speaker Takahiro Shima (Division of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital)

Sponsor Kyowa Kirin Co., Ltd.

LS3-18 Infectious disease management in allo-HSCT: focus on CMV

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

Chair Yuta Katayama (Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital)

Speaker Keiko Fukunaga (Department of Hematology, Nippon Medical School Hospital)

Sponsor MSD K.K.

9-Oct (Fri) 16:40–17:25

ES1-1 Current and Emerging Treatments for Relapsed/Refractory Multiple Myeloma

[No.1 Kyoto International Conference Center 1F Main Hall]

Chair Shigeki Ito (Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University)

The New Era of Bispecific Antibodies (Teclistamab/Talquetamab) ~ Including Combination Therapies~

Speaker Tadao Ishida (Japanese Red Cross Medical Center)

Sponsor Johnson & Johnson

ES1-2

Live Recording On-demand

[No.2 Kyoto International Conference Center 2F Room A]

Chair Yoshiaki Ogawa (Department of Hematology and Oncology, Tokai University School of Medicine)

Efficacy and Safety of the Higher Initial Dose and Accelerated dose Titration (HIDAT) BESREMi Regimen in Patients with Polycythemia Vera

Speaker Takuya Nunomura (Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital)

The real-world experience of initiating the BESREMi in the clinical practice

Speaker Masako Toyosaki (Department of Hematology and Oncology, Tokai University School of Medicine)

Sponsor PharmaEssentia Japan KK

ES1-3 Current Status of CLL Treatment and the Role of BCL2 Inhibitors

[No.3 Kyoto International Conference Center 2F Room B-1]

- Chair** Nobuhiko Uoshima (Department of Hematology, Japanese Red Cross Kyoto Daini Hospital)
- Speaker** Takahiro Kumode (Department of Hematology and Rheumatology, Kindai University)
- Sponsor** AbbVie GK

ES1-4 Infectious Disease Management in the Era of Novel Immunotherapies: From Infection Risks of Bispecific Antibodies and Other Emerging Therapies to Vaccination and Treatment Strategies

[No.4 Kyoto International Conference Center 2F Room B-2]

- Chair** Shuji Ozaki (Tokushima Prefectural Central Hospital, Department of Hematology)
- Speaker** Keiji Okinaka (Division of Infectious Diseases, National Cancer Center Hospital East, Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
- Sponsor** Pfizer Japan Inc. Medical Affairs

ES1-5 Current Frontiers in the Treatment of MF and GVHD

[No.5 Kyoto International Conference Center 1F Sakura]

- Chair** Hirohisa Nakamae (Department of Hematology, Osaka Metropolitan University Graduate School of Medicine)
- MF Treatment Strategies Aimed at Improving Overall Survival**
- Speaker** Katsuto Takenaka (Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine)
- Treatment Strategies Using Jakavi for Acute and Chronic GVHD**
- Speaker** Daigo Hashimoto (Department of Hematology, Hokkaido University Faculty of Medicine)
- Sponsor** Novartis Pharma K.K.

ES1-6 Management after Allogeneic Hematopoietic Stem Cell Transplantation – GVHD and Infection Control –

[No.6 Kyoto International Conference Center 1F Room C-1]

- Chair** Takehiko Mori (Hematology, Institute of Science Tokyo)
- Speaker** Hisashi Yamamoto (Department of Hematology/ Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Federation of National Public Service Personnel Mutual Aid Associations)
- Sponsor** Japan Medical Office, Takeda Pharmaceutical Company Limited.

ES1-7 Advancing Patient-Centered Care Through Shared Decision Making

[No.7 Kyoto International Conference Center 1F Room C-2]

Chair Takayuki Tabayashi (Saitama Medical Center, Saitama Medical University)

Shared Decision Making in an Expanding Treatment Landscape: Optimizing Decisions Based on Patient Values

Speaker Noriyuki Katsumata (Nippon Medical School Musashi Kosugi Hospital)

What Would You Do? — Challenges and Best Practices in Shared Decision Making

Panelist Minoru Kanaya (Aiiiku Hospital)

Noriyuki Katsumata (Nippon Medical School Musashi Kosugi Hospital)

Sponsor BeOne Medicines Japan

ES1-8 Regional Collaboration in Hemophilia Care

– Roles and Future Perspectives of Regional Core Hospitals and Affiliated Care Facilities –

[No.8 Kyoto International Conference Center 1F Room D]

Chair Kagehiro Amano (Department of Laboratory Medicine, Tokyo Medical University)

Better Together: Boosting Patient Satisfaction Through Clinic-Hospital Collaboration in Hemophilia Care

Speaker Mayuko Kishimoto (YASUMAYU Family Clinic)

The Role of ALTUVIII[®] in Hemophilia Patients with Lifestyle-Related Diseases and Comorbidities

Speaker Kazuho Morichika (Division of Endocrinology Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine Graduate School of Medicine University of the Ryukyus)

Sponsor Sanofi K.K.

ES1-9 The Frontline of Multiple Myeloma Treatment: Recent Evidence and New Modalities

[No.9 Kyoto International Conference Center 1F Room E]

Chair Hiroyuki Takamatsu (Faculty of Transdisciplinary Sciences for Innovation, Institute of Transdisciplinary Sciences for Innovation, Kanazawa University)

Speaker Daisuke Minakata (Division of Hematology, Department of Medicine, Jichi Medical University)

Sponsor GlaxoSmithKline K.K.

ES1-10 Treatment and Perioperative Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

[No.10 Kyoto International Conference Center 1F Room F]

Chair Motoshi Ichikawa (Department of Hematology, NTT Medical Center Tokyo)

Patient-Managed PNH Treatment –Pegcetacoplan as a Therapeutic Option–

Speaker Yasuyoshi Morita (Hematol and Rheumatol, Kindai University Faculty of Medicine)

Experience of Cardiac Surgery in a Patient with PNH Treated with Pegcetacopla

Speaker Seiko Iki (Departments of Clinical Laboratory and Hematology, Japanese Red Cross Medical Center)

Sponsor Asahi Kasei Therapeutics Corporation

ES1-12 A Decade of Carfilzomib in Multiple Myeloma: New Challenges Ahead

[No.12 Kyoto International Conference Center 1F Room H]

Chair Makoto Sasaki (Juntendo University, Department of Hematology)
Redefining the Scientific Role of Carfilzomib in the Era of CAR-T and Bispecific Antibodies

Speaker Daisuke Ogiya (Department of Hematology and Oncology, Tokai University School of Medicine)

The Value of Carfilzomib in the Era of CAR-T Cell Therapy and Bispecific Antibodies: Perspectives on Bridging Strategies and the Management of Older Adults

Speaker Yuichi Horigome (Department of Transfusion and Cell Transplantation, Kitasato University School of Medicine)

Sponsor ONO PHARMACEUTICAL CO., LTD.

ES1-13 Risk-Benefit Profile of Hemophilia Treatment with the Anti-TFPI Therapy Alhemo® (Tentative Title)

[No.13 Kyoto International Conference Center 2F Room I]

Chair Kotaro Shirakawa (Department of Hematology and Oncology, Kyoto University Hospital)

Speaker Nobuaki Suzuki (Department of Transfusion Medicine, Nagoya University Hospital)

Sponsor Novo Nordisk Pharma Ltd.

ES1-14 Treatment Strategy for Aplastic Anemia: Current Positioning of Romiplostim

[No.14 Kyoto International Conference Center 2F Room J]

Chair Hirohito Yamazaki (Division of Medical Safety Medicine, Kanazawa University Hospital)

Speaker Shuku Sato (Division of Hematology, Shonan Kamakura General Hospital)

Sponsor Kyowa Kirin Co., Ltd.

■ES1-15 Current Landscape of Gene Therapy in Japan: Towards Establishing an Appropriate Provision System

[No.15 Kyoto International Conference Center 2F Room K]

- Chair** Tsukasa Ohmori (Department of Biochemistry, Jichi Medical University School of Medicine)
- Speaker** Yoshikazu Yonemitsu (R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University.)
- Sponsor** CSL Behring K.K. Medical Affairs

■ES1-16 Standardization and Clinical Practice in Acquired Hemophilia A Management

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

- Chair** Yoshinobu Seki (Department of Hematology, Niigata University Medical and Dental Hospital)
- Key Points in the Diagnosis and Treatment of Acquired Hemophilia A**
- Speaker** Masahiro Takeyama (Division of Hemophilia, National Hospital Organization, Osaka National Hospital)
- Our Institutional Strategy for Acquired Hemophilia A: Achieving Rapid Diagnosis and Early Treatment**
- Speaker** Kazuya Okada (Department of Hematology/Oncology, Kurashiki Central Hospital)
- Sponsor** CHUGAI PHARMACEUTICAL CO., LTD.

■ES1-17 Potential of HDAC inhibitor for relapsed/refractory PTCL: Focusing on nodal TFH Lymphoma

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

- Chair** Akihiro Tomita (Department of Hematology, School of Medicine, Fujita Health University)
- Speaker** Ilseung Choi (Department of Hematology and Cell Therapy, NHO Kyushu Cancer Center)
- Sponsor** Meiji Seika Pharma Co., Ltd.

■ES1-18 Real-world experience of Ide-cel for multiple myeloma –the importance of bridging therapy–

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

- Chair** Emiko Sakaida (Department of Hematology, Chiba University Hospital)
- Speaker** Nobuhiro Tsukada (Department of Hematology Japanese Red Cross Medical Center)
- Sponsor** Bristol Myers Squibb K.K.

10-Oct (Sat) 17:05—17:50

ES2-1 A Patient-Focused Approach to Multiple Myeloma with Sarclisa Subcutaneous

【No.1 Kyoto International Conference Center 1F Main Hall】

- Chair** Kazutaka Sunami (Department of Hematology, NHO Okayama Medical Center)
- Speaker** Satoshi Ito (Department of Hematology, Yamagata University Hospital)
- Speaker** Takafumi Tsushima (Department of Hematology and Oncology, Japanese Red Cross Narita Hospital)
- Speaker** Teruhito Takakuwa (Department of Hematology Wakakusa-Daiichi Hospital)
- Sponsor** Sanofi K.K.

ES2-2 Clinical Update of AL Amyloidosis

【No.2 Kyoto International Conference Center 2F Room A】

- Chair** Chihiro Shimazaki (JCHO Kyoto Kuramaguchi Medical Center)
- Speaker** Yawara Kawano (Department of Hematology, Rheumatology and Infectious Disease, Faculty of Life Sciences, Kumamoto University)
- Sponsor** Alexion Pharma G.K.

ES2-3 Defining the Characteristics of First-Line IBR+VEN for CLL

【No.3 Kyoto International Conference Center 2F Room B-1】

- Chair** Yasushi Takamatsu (Department of Medical Oncology, Hematology, and Infectious Diseases, Faculty of Medicine, Fukuoka University)
- Speaker** Sadao Aoki (Division of Hematology, Department of Medical Technology, Niigata University of Pharmacy and Medical and Life Sciences)
- Sponsor** Johnson & Johnson

ES2-4 Updates in Treatment Strategies for PNH Based on the Latest Clinical Data and the Revised J-PIG Guidelines

【No.4 Kyoto International Conference Center 2F Room B-2】

- Chair** Masatoshi Sakurai (Division of Hematology, Department of Medicine, Keio University School of Medicine)
- Speaker** Toshio Kitawaki (Department of Hematology, Kawasaki Medical School)
- Sponsor** Novartis Pharma K.K.

ES2-5 Clinical Applications of Gene Panel Testing in MDS

[No.5 Kyoto International Conference Center 1F Sakura]

- Chair** Takahiro Maeda (Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences)
- Speaker** Yasuhito Nannya (Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo)
- Sponsor** Otsuka Pharmaceutical Co., Ltd.

ES2-6 Current Status and Future Perspectives of VEN+AZA Therapy in AML

[No.6 Kyoto International Conference Center 1F Room C-1]

- Chair** Koji Ando (Unit for Radiation Effects on Humans, Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki)
- Speaker** Yuichi Ishikawa (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine)
- Sponsor** AbbVie GK

ES2-7 CD30 Targeted Therapy in Peripheral T-cell Lymphoma: Current and Future Perspectives

[No.7 Kyoto International Conference Center 1F Room C-2]

- Chair** Dai Maruyama (Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
- Speaker** Steven Michael Horwitz (Nonna's Garden Foundation/Memorial Sloan Kettering Cancer Center/Department of Medicine, Weill Cornell Medical College)
- Sponsor** Takeda Pharmaceutical Company Limited

ES2-8 Practical Considerations for Delivering CAR T-Cell Therapy

[No.8 Kyoto International Conference Center 1F Room D]

- Chair** Satoshi Yoshihara (Department of Respiratory Medicine and Hematology, Hyogo Medical University)
- Toward Sustainable CAR T-Cell Therapy**
— Experience from Kyoto University Hospital —
- Speaker** Tomoyasu Jo (Kyoto University Hospital)
- Reliable, Timely Delivery as a Clinical Value Driver**
- Speaker** Miguel-Angel Perales (Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College)
- Sponsor** Gilead Sciences K.K.

■ES2-9

[No.9 Kyoto International Conference Center 1F Room E]

Chair Itaru Matsumura (Department of Hematology and Rheumatology, Kindai University Faculty of Medicine)

Supporting Treatment Choices in Follicular Lymphoma through Shared Decision-Making: Making Sense of Options, Pros, Cons, and Values with “O-CHI-TA-KA”

Speaker Kazuhiro Nakayama (Graduate School of Nursing Science, St. Luke's International University)

The role of bi-specific antibodies and SDM in the treatment of relapsed/refractory follicular lymphoma

Speaker Ritsuro Suzuki (Department of Hematology and Oncology, Faculty of Medicine, Shimane University)

Sponsor CHUGAI PHARMACEUTICAL CO., LTD.

■ES2-10 Treatment Strategies for CLL in the Era of BTK Inhibitors: Considering the Role of Pirtobrutinib

[No.10 Kyoto International Conference Center 1F Room F]

Chair Shuichi Ota (Department of Hematology, Sapporo Hokuyu Hospital)

Speaker Hiroyuki Takahashi (Department of Hematology and Rheumatology, Yokohama City University Hospital)

Sponsor Nippon Shinyaku Co., Ltd.

■ES2-12 AML: Pathobiology and Treatment Strategies—Past, Present, and Future

[No.12 Kyoto International Conference Center 1F Room H]

Chair Kentaro Fukushima (Department of Hematology and Oncology, The University of Osaka, Graduate School of Medicine)

Speaker Naoko Hosono (Department of Blood Transfusion, University of Fukui Hospital)

Sponsor Sumitomo Pharma Co., Ltd.

■ES2-13 Supportive Care for Multiple Myeloma in the CAR-T/BsAb Era: SID Management and IgRT

[No.13 Kyoto International Conference Center 2F Room I]

Chair Hirokazu Tanaka (Department of Hematology and Rheumatology, Kindai University Faculty of Medicine/Center for Transfusion Medicine and Cell Therapy, Kindai University Hospital)

Infection Management in Bispecific Antibody Therapy for Multiple Myeloma: Supportive Care Looking Ahead to the Upcoming Revised Guidelines

Speaker Sho Ikeda (Department of Hematology, Japanese Red Cross Akita Hospital)

Hypogammaglobulinemia and Infections After CAR-T Therapy: The Role of IgRT and Infection Management

Speaker Kohei Okada (Department of Hematology, Sapporo Hokuyu Hospital)

Sponsor Takeda Pharmaceutical Company Limited, Japan Medical Office

ES2-14 Treatment Strategies for Transplant-Ineligible MCL in the Era of BTK Inhibitors

– The Role of Acalabrutinib plus Bendamustine and Rituximab –

【No.14 Kyoto International Conference Center 2F Room J】

- Chair** Kana Miyazaki (Department of hematology and Oncology, Mie University Graduate School of Medicine)
- Speaker** Masuho Saburi (Department of Transfusion Medicine, Oita Prefectural Hospital)
- Sponsor** AstraZeneca K.K.

ES2-15 Thrombosis in the pathogenesis and treatment of Immune thrombocytopenia (ITP)

【No.15 Kyoto International Conference Center 2F Room K】

- Chair** Kenji Yokoyama (Tokai University Hachioji Hospital Department of Hematology and Oncology)
- Speaker** Shugo Kowata (Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University)
- Sponsor** Sobi Japan/Asahi Kasei Therapeutics Corporation

ES2-16 How Will Liso-cel Transform the Management of Indolent Lymphomas? –Who Should Receive Liso-cel and When?–

【No.16 The Prince Kyoto Takaragaike 1F Royal Room】

- Chair** Koji Kato (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences)
- Speaker** Tatsu Shimoyama (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)
- Sponsor** Bristol Myers Squibb K.K.

ES2-17 Core Treatment Principles Amid the Expanding Landscape of Complement Inhibitor Therapies

【No.17 The Prince Kyoto Takaragaike B1F Rose Room】

- Chair** Kaichi Nishiwaki (Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Chiba, Japan)
- Speaker** Tatsuya Kawaguchi (Kumamoto Health Science University)
- Sponsor** CHUGAI PHARMACEUTICAL CO., LTD.

ES2-18 Treatment Strategies with Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia

【No.18 The Prince Kyoto Takaragaike B2F Gold Room】

- Chair** Takahiro Yamauchi (Department of Hematology and Oncology, University of Fukui)
- Speaker** Junichi Sugita (Department of Hematology, Sapporo Hokuyu Hospital)
- Sponsor** Pfizer Japan Inc.

10-Oct (Sat) 7:30–8:15

**MS2-1 The “SROT” as a New Therapeutic Goal in ITP
–What Can We Learn from TFR in CML?**

【No.1 Kyoto International Conference Center 1F Main Hall】

- Chair** Tatsunori Goto (Department of Blood Transfusion, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital)
- Speaker** Yukari Shirasugi (Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences
Department of Hematology, Mitsui Memorial Hospital)
- Sponsor** Novartis Pharma K.K. Medical Affairs

**MS2-2 Clinical Debate
Emerging Clinical Questions Following the Introduction of
Daratumumab**

【No.2 Kyoto International Conference Center 2F Room A】

- Chair** Masashi Sawa (Anjo Kosei Hospital Department of Hematology and Oncology)
- Reappraising the Value of Transplantation in the Context of Quadruplet Therapy**
- Speaker** Kotaro Miyao (Anjo Kosei Hospital Department of Hematology and Oncology)
- Reappraising the Role of Non-Transplant Strategies in the Context of Quadruplet Therapy**
- Speaker** Kazuhito Suzuki (Division of Clinical Oncology and Hematology, The Jikei University School of Medicine)
- Sponsor** Johnson & Johnson

**MS2-3 Update on the Management of Extranodal NK/T-cell Lymphoma:
Guidelines and Treatment Strategies for Relapsed or Refractory
Disease**

【No.3 Kyoto International Conference Center 2F Room B-1】

- Chair** Sachiko Seo (Department of Hematology, Tokyo Women's Medical University)
- Speaker** Makoto Yoshimitsu (Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University)
- Sponsor** CHUGAI PHARMACEUTICAL CO., LTD.

**MS2-4 The Latest Treatment of Large B-Cell Lymphoma
– Toward the Improvement of Treatment Outcomes –**

【No.4 Kyoto International Conference Center 2F Room B-2】

- Chair** Go Yamamoto (Department of Hematology, Toranomon Hospital)
- Speaker** Kazuyuki Shimada (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine)
- Sponsor** Gilead Sciences K.K.

■MS2-5 ITP as Complex Immune Dysregulation: A New Treatment Strategy with the BTK Inhibitor Rilzabrutinib

[No.5 Kyoto International Conference Center 1F Sakura]

Chair Yoshiaki Tomiyama (Uegahara Hospital)
Speaker Jun Yamanouchi (Division of Blood Transfusion and Cell Therapy, Ehime University Hospital)
Sponsor Sanofi K.K.

■MS2-6 Real-World Management of Acquired Hemophilia A: Hemostatic Assessment and Hands-on Experience with Obizur

[No.6 Kyoto International Conference Center 1F Room C-1]

Chair Teruhisa Fujii (Division of Transfusion Medicine and Hemophilia Treatment Center, Hiroshima University Hospital)
Speaker Takashi Onaka (Department of Hematology, Japanese Red Cross Osaka Hospital)
Sponsor Takeda Pharmaceutical Company Limited

■MS2-7 How Can We Apply the Evidence in Clinical Practice? – Messages from Real-World Experience with Brukinsa –

[No.7 Kyoto International Conference Center 1F Room C-2]

Chair Tsuyoshi Muta (Hiroshima Red Cross Hospital)
Speaker Yasushi Hiramatsu (Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital)
Sponsor BeOne Medicines Japan

■MS2-8 Liquid Biopsy in CNS Lymphoma: How Far Can Minimally Invasive Approach Advance Patient Care?

[No.8 Kyoto International Conference Center 1F Room D]

Chair Eisei Kondo (Department of Hematology, Kawasaki medical school)
Speaker Chisako Iriyama (Department of Hematology, Fujita Health University School of Medicine)
Sponsor ONO PHARMACEUTICAL CO., LTD.

■MS2-9 Myelofibrosis in the Multi-JAK Inhibitor Era: From Anemia Assessment to Treatment Selection

[No.9 Kyoto International Conference Center 1F Room E]

Chair Keita Kirito (Department of Hematology and Oncology, University of Yamanashi)
Speaker Kotaro Shide (Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki)
Sponsor GlaxoSmithKline K.K.

■MS2-10 Reconsidering Hemostatic Strategies in Acquired Hemophilia A

【No.10 Kyoto International Conference Center 1F Room F】

- Chair** Eriko Morishita (Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University)
- Speaker** Keiji Nogami (Department of Pediatrics, Nara Medical University)
- Sponsor** Novo Nordisk Pharma Ltd.

■MS2-12 Treatment Strategies for ITP ~Characteristics and Positioning of Avatrombopag~

【No.12 Kyoto International Conference Center 1F Room H】

- Chair** Akiyoshi Takami (Department of Internal Medicine, Division of Hematology, Aichi Medical University School of Medicine)
- Speaker** Hisashi Kato (Department of Blood Transfusion and Cell Therapy, The University of Osaka Hospital)
- Sponsor** ASAHI KASEI THERAPEUTICS CORPORATION

■MS2-13 Transplant-Integrated Treatment Strategy for Newly Diagnosed FLT3-ITD-Mutated AML

【No.13 Kyoto International Conference Center 2F Room I】

- Chair** Yoshihiro Inamoto (Department of Hematology & Cellular Therapy, Fujita Health University Hospital)
- Speaker** Yuho Najima (Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)
- Sponsor** DAIICHI SANKYO COMPANY, LIMITED.

■MS2-14 Toward Shared Decision Making in Adult Hemophilia Care

【No.14 Kyoto International Conference Center 2F Room J】

- Chair** Takeshi Matsumoto (Department of Transfusion Medicine and Cell Therapy Saitama Medical Center, Saitama Medical University)
- Speaker** Tazuko Tokugawa (Division of Hematology Hyogo Medical University Hospital)
- Sponsor** CSL Behring K.K.

■MS2-15 Current and Future Perspectives in Myelofibrosis Treatment

【No.15 Kyoto International Conference Center 2F Room K】

- Chair** Daigo Akahane (Department of Hematology, Tokyo Medical University)
- Speaker** Yuka Sugimoto (Department of Hematology and Oncology, Graduate School of Medicine, Mie University)
- Sponsor** Sumitomo Pharma Co., Ltd.

**■MS2-16 The Frontiers of MRD Assessment in AML
— Current Methods and Challenges—**

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

- Chair** Masahiro Onozawa (Department of Laboratory and Transfusion Medicine, Hokkaido University Hospital)
- Speaker** Hayato Maruoka (Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Japan)
- Sponsor** Astellas Pharma Inc. Medical Affairs

**■MS2-17 Current Practice and Perspectives in BPDCN Treatment:
The Clinical Value of Tagraxofusp**

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

- Chair** Akira Yokota (Department of Hematology, Chiba Aoba Municipal Hospital)
- Speaker** Makoto Onizuka (Department of Hematology and Oncology, Tokai University School of Medicine)
- Sponsor** Nippon Shinyaku Co., Ltd.

■MS2-18

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

- Chair** Kazuhito Yamamoto (Aichi Cancer Center)
- Unmet Needs and Treatment Strategies in Relapsed Follicular Lymphoma**
- Speaker** Hirotoshi Kamata (Department of Hematology, Kitasato University School of Medicine)
- An Immune-Based Approach to Follicular Lymphoma Treatment: The Basic Science and Future Perspectives of Bispecific Antibodies**
- Speaker** Yusuke Furukawa (Center for Medical Education, Teikyo University of Science)
- Sponsor** Genmab KK, Medical Affairs / AbbVie GK, Medical

11-Oct (Sun) 7 : 50—8 : 35

■MS3-1 Practical Use of BLENREP in the Treatment of Relapsed/Refractory Multiple Myeloma: Perspectives from Hematologists and Ophthalmologists

[No.1 Kyoto International Conference Center 1F Main Hall]

- Chair** Ichiro Hanamura (Department of Internal Medicine, Department of Hematology, Aichi Medical University)
- Speaker** Toshinari Funaki (Department of Ophthalmology, Japanese Red Cross Medical Center)
- Sponsor** GlaxoSmithKline K.K.

MS3-2 The Current State of Precision Medicine in Lymphoma

【No.2 Kyoto International Conference Center 2F Room A】

- Chair** Hiromi Iwasaki (Department of Hematology, National Hospital Organization Kyushu Medical Center)
- Speaker** Keisuke Kataoka (Division of Hematology, Department of Medicine, Keio University School of Medicine / Division of Molecular Oncology, National Cancer Center Research Institute)
- Sponsor** Incyte Biosciences Japan G.K.

MS3-3 wAIHA Beyond Anemia: The Burden Behind Hemoglobin Levels

【No.3 Kyoto International Conference Center 2F Room B-1】

- Chair** Hideo Harigae (Tohoku University)
- Speaker** Yasutaka Ueda (Department of Hematology and Oncology, Graduate School of Medicine, Osaka University)
- Sponsor** Medical Affairs Division, Johnson & Johnson

MS3-4 Interferon Signaling and the Immune System

【No.4 Kyoto International Conference Center 2F Room B-2】

- Chair** Kenji Ishitsuka (Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University)
- Speaker** Takuro Kameda (Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki)
- Sponsor** PharmaEssentia Japan KK

MS3-5 Optimizing First-Line Treatment: The Significance of Obinutuzumab + Bendamustine in the Era of Cellular Immunotherapies

【No.5 Kyoto International Conference Center 1F Sakura】

- Chair** Hitoshi Hanamoto (Division of Hematology, Kindai University Nara Hospital)
- Speaker** Hiromichi Takahashi (Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine)
- Sponsor** CHUGAI PHARMACEUTICAL CO., LTD. / Nippon Shinyaku Co.,Ltd.

MS3-6 A Decade of Carfilzomib in Multiple Myeloma: New Challenges Ahead

【No.6 Kyoto International Conference Center 1F Room C-1】

Chair Koji Nagafuji (Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine)

Deep Dive into Proteasome Inhibitors: From Bench to Bedside

Speaker Naoya Mimura (Transfusion Medicine and Cell Therapy, Chiba University Hospital)

Building the Runway for Next-Generation Therapies with High-Dose Carfilzomib

Speaker Riku Nagao (The Jikei University School of Medicine, Kashiwa Hospital)

Sponsor ONO PHARMACEUTICAL CO., LTD.

MS3-7

【No.7 Kyoto International Conference Center 1F Room C-2】

Chair Hiroshi Handa (Department of Hematology, Gunma University Hospital)

Unveiling Real-World Data Research Through Medical Statistics

Speaker Satoshi Morita (Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine)

Elranatamab in the Real World: Optimizing Treatment Strategies for RRMM

Speaker Masataka Takeshita (Department of Hematology, Tokyo-Kita Medical Center / International Myeloma Center for Advanced Research and Treatment)

Sponsor Pfizer Japan Inc. Oncology Medical Affairs

MS3-8 Decision-Making in CML Based on Updated Guidelines

【No.8 Kyoto International Conference Center 1F Room D】

Chair Shinya Kimura (Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University)

Speaker Tomoiku Takaku (Department of Hematology, Saitama Medical University Hospital)

Sponsor Novartis Pharma K.K.

MS3-9 Pathological Diagnosis of Primary Cold Agglutinin Disease (CAD) Underlying Lymphoproliferative Disorders and the Importance of Quality of Life in CAD Treatment

[No.9 Kyoto International Conference Center 1F Room E]

Chair Yosuke Masamoto (Department of Blood Transfusion, The University of Tokyo Hospital)

Differential Diagnosis of CAD and CAS: Toward Accurate Diagnosis and Clinical Collaboration

Speaker Naoko Asano (Department of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center)

Cold Agglutinin Disease: Autoimmune Disease or Clonal B-cell Disorder? — Therapeutic Implications Based on Disease Pathogenesis

Speaker Naoshi Obara (Department of Medical Sciences (Laboratory Hematology) and Department of Hematology, Faculty of Medicine, University of Tsukuba, Japan)

Sponsor Recordati Rare Diseases Japan K.K

MS3-10 Diagnosing von Willebrand Disease with Confidence: A Practical Guide for Hematologists

[No.10 Kyoto International Conference Center 1F Room F]

Chair Takayuki Ikezoe (Department of Hematology, Fukushima Medical University)

Speaker Azusa Nagao (Department of Hematology and Oncology, Kansai Medical University Hospital)

Sponsor Takeda Pharmaceutical Company Limited

MS3-12 Current Guideline-Based Management of DIC in Hematologic Malignancies: From Evidence to Clinical Practice

[No.12 Kyoto International Conference Center 1F Room H]

Chair Toru Kiguchi (Department of Hematology, and Blood Transfusion Department, Dokkyo Medical University Saitama Medical Center)

Speaker Hiroyuki Fujita (Hematology Department, Saiseikai Yokohama Nanbu Hospital)

Sponsor Asahi Kasei Therapeutics Corporation

MS3-13 Strategies for Preventing Hepatitis Due to Hepatitis B Virus Reactivation: Key Considerations in Hematology Practice

[No.13 Kyoto International Conference Center 2F Room I]

Chair Yuya Koda (Division of Hematology, Department of Medicine, Keio University.)

Speaker Satoshi Mochida (Department of Gastroenterology and Hepatology, Saitama Medical University)

Sponsor Gilead Sciences K.K.

■MS3-15 Treatment and Management for FLT3-ITD-Positive AML in the Elderly

[No.15 Kyoto International Conference Center 2F Room K]

- Chair** Ken-ichi Matsuoka (Department of Hematology, Endocrinology and Metabolism Tokushima University Graduate School of Biomedical Sciences)
- Speaker** Senji Kasahara (Gifu Municipal Hospital)
- Sponsor** Daiichi Sankyo Medical Affairs

■MS3-16 Is Combination Therapy the Breakthrough for Relapsed/Refractory Mantle Cell Lymphoma? ~The Potential of Ibrutinib Plus Venetoclax~

[No.16 The Prince Kyoto Takaragaike 1F Royal Room]

- Chair** Momoko Nishikori (Department of Human Health Sciences, Graduate School of Medicine, Kyoto University)
- Speaker** Taiga Kuroi (Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers)
- Sponsor** Johnson & Johnson

■MS3-17 Evolving Treatment Landscape for DLBCL- Current Practice and Future Perspectives in the Era of Immunotherapy

[No.17 The Prince Kyoto Takaragaike B1F Rose Room]

- Chair** Jun Ando (Division of Cell Therapy and Blood Transfusion Medicine, Department of Hematology, Juntendo University School of Medicine)
- Speaker** Shinichi Makita (Department of Hematology Oncology, National Cancer Center Hospital)
- Sponsor** Bristol Myers Squibb K.K.

■MS3-18 Toward Standardization of Acquired TTP Management – The 2026 TTP Guideline Update and Practical Approaches to Diagnosis and Treatment –

[No.18 The Prince Kyoto Takaragaike B2F Gold Room]

- Chair** Takahiro Suzuki (Department of Hematology, Kitasato University School of Medicine)
- Diagnostic and Treatment Guidelines for TTP 2026: Key Revisions**
- Speaker** Masanori Matsumoto (Department of Hematology, Nara Medical University)
- Diagnosis and Management of Acquired Thrombotic Thrombocytopenic Purpura in the Acute Care Hospital Setting**
- Speaker** Tadakazu Kondo (Department of Hematology, Kobe City Medical Center General Hospital)
- Sponsor** Sanofi K.K.

10-Oct (Sat) 10 : 40—11 : 10

IS2-2 Next-Generation Antibody Therapeutics: Current Landscape and Future Directions

【No.2 Kyoto International Conference Center 2F Room A】

- Chair** Tomomi Toubai (Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Clinical Research and Trials Center/Hematology Division)
- Speaker** Masahiro Yasunaga (Division of Developmental Therapeutics, National Cancer Center, Japan)
- Sponsor** Genmab KK, Medical Affairs / AbbVie GK, Medical

IS2-3 Real world data of cold agglutinin disease – recent update on sutimlimab

【No.3 Kyoto International Conference Center 2F Room B-1】

- Chair** Kazuhiko Ikeda (Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University)
- Speaker** Joan Cid (Department of Hemotherapy and Hemostasis, Hospital Clinic, Barcelona)
- Sponsor** Recordati Rare Diseases Japan K.K

11-Oct (Sun) 11 : 00—11 : 30

IS3-2 Frontiers in the Management of Systemic AL Amyloidosis: Current Treatment Strategies and Future Perspectives for Addressing Unmet Needs

【No.2 Kyoto International Conference Center 2F Room A】

- Chair** Hironobu Naiki (University of Fukui)
- Speaker** Shinichi Fuchida (Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center)
- Sponsor** Alexion Pharma G.K. Medical Affairs Division

IS3-3 Optimizing Treatment Strategy for JAK Inhibitors in Myelofibrosis

【No.3 Kyoto International Conference Center 2F Room B-1】

- Chair** Takuji Yamauchi (Hematology, Oncology & Cardiovascular medicine, Kyushu University Hospital)
- Speaker** Jean-Jacques Kiladjian (Clinical Investigation Center, Hôpital Saint-Louis/Department of Clinical Pharmacology, Université Paris Cité, France)
- Sponsor** Recordati Rare Diseases Japan K.K